The decline in the company's share price came as its shares traded ex-date following the announcement of a ₹32 per share ...

Germany is asking those who received the first dose of the AstraZeneca COVID-19 vaccine to get their second dose from a different brand. The country hopes mixing vaccines will boost the rate and ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Pfizer’s Nurtec and AstraZeneca’s Breztri topped an analysis of the digital and omnichannel marketing strategies of the top pharma brands released Thursday morning. Trinity Life Sciences published its ...

Highwire names 5W, Ketchum alum Michael O’Brien as CEO Jess Ruderman May 15, 2025 ‘Hollywood can impact change’: Ryan Reynolds on raising awareness about Parkinson’s-related hallucinations Lecia ...

AstraZeneca Plc agreed to buy Icosavax Inc. for as much as $1.1 billion ... The deal also includes a contingent value right of as much as $5 per share if experimental products reach certain ...

| AstraZeneca’s COVID-19 vaccine has an official name, Vaxzevria, now approved in Europe. While a new name may not be enough to hurdle its rollout communication glitches, an anticipated FDA ...

AstraZeneca moved to further bulk up its respiratory drug business with the acquisition of Actavis PLC’s branded respiratory drug business in the U.S. and Canada for an initial $600 million.

AstraZeneca plans to spend about $450 million building a factory in China making inhalers to treat "smoker's lung", doubling down on the world's No.2 pharmaceuticals market as the drugmaker ...